Baekje Pharmaceutical said that it would exclusively distribute all of Leo Pharma's dermatology products for three years starting from July.
|Leo Pharma CEO Shin Jung-bum (left) and Baekje CEO Kim Dong-goo hold their agreement at Bakeje Pharmaceutical headquarters in Guro-gu, Seoul, on Monday.|
Under their accord, the two companies plan to strengthen their competitiveness and lead the local pharmaceutical market based on Leo's excellent product capability and Baekje's national distribution network, product sales force, and real-time data management system, the company said.
"Partnership with Baekje, which has an excellent local distribution network, rapid delivery, and real-time data management system, is the best choice for both companies," Leo Pharma CEO Shin Jung-bum said. "By partnering with Baekje Pharmaceuticals, Leo pharma will take the lead in developing treatments for skin diseases such as psoriasis and atopic dermatitis, and will provide more therapeutic benefits to local patients."
Baekje CEO Kim Dong-goo also said, "As the company has enough capacity for distribution services as well as third-party logistics services, it expects greater synergy in terms of cost reduction and efficiency in providing third-party logistics services to Leo Pharma."
<© Korea Biomedical Review, All rights reserved.>